Dosing begins in topical CBD pain study
Released
Released
Announcement PDF
ASX Limited
Market Announcements Office
Dosing Commences for CBD Topical Osteoarthritis Study in collaboration with
the Lambert Initiative
Highlights:
•
•
•
Avecho today announced patient dosing has commenced for its Phase IIa Study examining a
topical CBD gel for the management of pain associated with arthritis of the hand.
The Study tests a proprietary formulation, developed by Avecho, incorporating its TPM®
technology, and examines whether topically applied CBD can provide relief from symptoms
of osteoarthritis.
The Study is being run in collaboration with the Lambert Initiative, a leading Australian
academic institute studying cannabinoid therapeutics.
Melbourne, Australia, 1 March 2022: Avecho Biotechnology Limited (ASX:AVE, “Avecho”, or “the
Company”) today announced it has commenced patient dosing for its Phase IIa Study (“the Study”)
examining whether topically applied cannabidiol (CBD) can provide relief from symptoms of
osteoarthritis.
The proof-of-concept Study is being run by Principal Investigator, Dr Daniel Lewis, from the Daniel
Lewis Rheumatology Centre and Co-Investigator, and Professor Iain McGregor, from the Lambert
Iniative, Australia’s leading research group for the discovery, development, and optimisation of safe
cannabinoid therapeutics,.
Avecho CEO, Dr Paul Gavin, said: “Osteoarthritis (OA) is a chronic and poorly managed pain
condition, with limited treatment options available. Increasingly, CBD is being prescribed for a range
of pain conditions, despite a relative absence of formal human clinical trials demonstrating its
effectiveness. Commencement of patient dosing is an important milestone in our ongoing efforts to
understand and quantify how it could help.”
The Study uses one of Avecho’s proprietary formulation vehicles incorporating its TPM®
technology. This formulation has already been shown to increase the dermal absorption of CBD in
laboratory experiments by five times.
Fifteen patients suffering painful arthritis of the fingers or thumb have successfully completed their
baseline assessments and have now begun their treatment regimen. The topical formulation will be
applied to painful joints of the fingers and/or thumb each day over a four week period. Assessment
will include pain scores, functional scores, and assessments of grip strength using a dynamometer.
High level results from the Study are expected Q2 2022. Positive results would support the further
clinical development of a topical CBD product.
- ENDS This announcement is authorised for release by the Board of Directors of Avecho Biotechnology
Limited.
Avecho Biotechnology Limited I ABN: 32 056 482
Unit 8A, 2A Westall Road, Hallmarc Business Park, Clayton VIC Australia 3168
Investor + General Enquiries
Ms Melanie Leydin
Company Secretary
Avecho Biotechnology Limited
+61 3 9002 5000
About Avecho
Avecho Biotechnology Limited develops and commercialises innovative Human and Animal Health
products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM®).
TPM® is derived from Vitamin E using unique, proprietary and patented processes and is proven to
enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.
Avecho's major projects include delivering TPM® enhanced injectable, oral and topical products for
the human health market and is also developing TPM® to enhance the feed efficiency and health of
livestock.
Forward-Looking Statements
Certain statements in this announcement are forward looking statements. Forward looking
statements can generally be identified by the use of words such as “anticipate”, “estimate”, “expect”,
“project”, “intend”, “plan”, “believe”, “target”, “may”, “assume” and words of similar import. These
forward-looking statements speak only as at the date of this announcement. These statements are
based on current expectations and beliefs and, by their nature, are subject to a number of known
and unknown risks and uncertainties that could cause the actual results, performances and
achievements to differ materially from any expected future results, performance or achievements
expressed or implied by such forward looking statements.
No representation, warranty or assurance (express or implied) is given or made by Avecho that the
forward-looking statements contained in this announcement are accurate, complete, reliable or
adequate or that they will be achieved or prove to be correct. Except for any statutory liability which
cannot be excluded, Avecho and its respective officers, employees and advisers expressly disclaim
any responsibility for the accuracy or completeness of the forward looking statements and exclude
all liability whatsoever (including negligence) for any direct or indirect loss or damage which may be
suffered by any person as a consequence of any information in this announcement or any error or
omission therefrom.
Subject to any continuing obligation under applicable law or relevant listing rules of the ASX, Avecho
disclaims any obligation or undertaking to disseminate any updates or revisions to any forward
looking statements in these materials to reflect any change in expectations in relation to any forward
looking statements or any change in events, conditions or circumstances on which any statement is
based. Nothing in these materials shall under any circumstances create an implication that there has
been no change in the affairs of Avecho since the date of the announcement.
Avecho Biotechnology Limited I ABN: 32 056 482
Unit 8A, 2A Westall Road, Hallmarc Business Park, Clayton VIC Australia 3168
Share your feedback
Discover